{"name": "Genfit", "permalink": "genfit", "crunchbase_url": "http://www.crunchbase.com/company/genfit", "homepage_url": "http://www.genfit.com/", "blog_url": "", "blog_feed_url": "", "twitter_username": "", "category_code": "biotech", "number_of_employees": null, "founded_year": null, "founded_month": null, "founded_day": null, "deadpooled_year": null, "deadpooled_month": null, "deadpooled_day": null, "deadpooled_url": null, "tag_list": "", "alias_list": "", "email_address": "", "phone_number": "+33 (0) 320 164 000", "description": "", "created_at": "Fri Mar 18 03:57:54 UTC 2011", "updated_at": "Fri Mar 18 03:58:27 UTC 2011", "overview": "\u003Cp\u003EGenfit SA, a biopharmaceutical company, engages in the research and development of drugs for the prevention and treatment of cardiometabolic and neurodegenerative diseases. The company focuses on various therapeutic areas, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer\u00e2\u20ac\u2122s diseases. Its lead proprietary program, GFT505, is an oral drug candidate under Phase II clinical trial for the treatment of pre-diabetes/diabetes. The company\u00e2\u20ac\u2122s products also include AVE0897 and SLV341, which are in Phase I clinical trial for the treatment of diabetes; SLV342, a pre-clinical product for the treatment of atherosclerosis; SAVX1, a pre-clinical products for the treatment of diabetes and vascular inflammation; BMGFT02, a pre-clinical product for the treatment of pre-diabetes/diabetes and beta-cell failure; and BMGFT01, a pre-clinical stage product for the treatment of Atherosclerosis. It has various collaboration, partnership, and strategic agreements with Sanofi-Aventis, Solvay group, Servier, and Merck. \u003C/p\u003E", "image":  {"available_sizes":    [[[150,       37],      "assets/images/resized/0012/6768/126768v1-max-150x150.png"],     [[218,       55],      "assets/images/resized/0012/6768/126768v1-max-250x250.png"],     [[218,       55],      "assets/images/resized/0012/6768/126768v1-max-450x450.png"]],   "attribution": null}, "products":  [], "relationships":  [{"is_past": false,    "title": "Chairman and CEO",    "person":     {"first_name": "Jean-Fran\u00c3\u00a7ois",      "last_name": "Mouney",      "permalink": "jean-franois-mouney"}}], "competitions":  [], "providerships":  [], "total_money_raised": "$0", "funding_rounds":  [], "investments":  [], "acquisition": null, "acquisitions":  [], "offices":  [{"description": "",    "address1": "Parc Eurasant\u00c3\u00a9",    "address2": "885, Avenue Eug\u00c3\u00a8ne Avin\u00c3\u00a9e",    "zip_code": "59120 ",    "city": "Loos",    "state_code": null,    "country_code": "FRA",    "latitude": null,    "longitude": null}], "milestones":  [{"description": "Genfit deal with sanofi-aventis worth up to $54.5M",    "stoned_year": 2010,    "stoned_month": 3,    "stoned_day": 17,    "source_url": "http://www.masshightech.com/stories/2011/03/14/daily53-Genfit-deal-with-sanofi-aventis-worth-up-to-545M.html",    "source_text": "",    "source_description": "Genfit deal with sanofi-aventis worth up to $54.5M",    "stoneable_type": "Company",    "stoned_value": null,    "stoned_value_type": null,    "stoned_acquirer": null,    "stoneable":     {"name": "Genfit",      "permalink": "genfit"}}], "ipo": null, "video_embeds":  [], "screenshots":  [], "external_links":  []}